SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

IMPLANTABLE DRUG DELIVERY SYSTEM

Yadav Shubham Devendra*, Awan Kumar Pandey
S.N College of Pharmacy Babupur (222132) Lakhauwa Jaunpur
*Corresponding Author

ABSTRACT
Implantable drug shipping systems (IDDS) constitute a sophisticated magnificence of healing technology designed to offer sustained, site-unique and managed launch of drugs, thereby overcoming many barriers of traditional dosage forms. These gadgets permit direct shipping of a healing agent to the goal tissue or systemic circulate with decreased dosing frequency, stepped forward affected person compliance, and minimized systemic aspect effects. IDDS can be passive (e.g., polymeric implants, biodegradable matrices) or active (e.g., osmotic pumps, microelectromechanical actuators) and are implemented throughout various fields which includes oncology, contraception, ophthalmology and persistent sickness management. Despite the vast advantages, demanding situations continue to be in biocompatibility, tool retrieval or biodegradation, cost, regulatory approval and long-time period reliability. Continued improvements in substances science, wi-fi actuation, miniaturization and closed-loop manage promise to increase the scope and efficacy of implantable shipping platforms.

KEYWORDS: *Implantable drug shipping system; Controlled release; Biodegradable polymers; Targeted therapy; Cancer treatment; Ocular implants; Hormonal therapy; Smart drug shipping.*

INTRODUCTION

Drug transport generation performs a vital function in figuring out the safety, efficacy, and affected person compliance of pharmacotherapy. Conventional dosage bureaucracy including oral capsules or parenteral injections frequently face sizeable demanding situations which includes bad bioavailability, fluctuating plasma drug concentrations, first-byskip metabolism, and the want for common administration. These barriers can cause suboptimal healing effects and bad affected person adherence, specifically in persistent situations requiring long-time period therapy (Malik, 2013; Fulzele et al., 2022).

To conquer those drawbacks, the idea of managed and centered drug transport structures has evolved, aiming to hold drug stages in the healing window for an prolonged duration. Among those, implantable drug transport structures (IDDS) constitute one of the maximum superior and promising approaches. These structures are designed to be surgically or minimally invasively located in the body—subcutaneously, intramuscularly, or close to the goal site—to supply healing retailers at a managed price for extended periods (Huanbutta et al., 2024).

Implantable structures provide numerous blessings over traditional routes. They offer sustained and site-unique drug launch, lessen systemic facet effects, put off the want for common dosing, and enhance affected person compliance (Amreen et al., 2023). Moreover, IDDS can pass organic limitations including the gastrointestinal tract and hepatic metabolism, making sure higher bioavailability of touchy molecules like peptides, proteins, and hormones (Malik, 2013).

Depending on their design, implantable structures can be passive—wherein drug launch is ruled with the aid of using diffusion, degradation, or osmotic mechanisms—or active, wherein microelectronic or mechanical additives manipulate launch on-demand (Puri et al., 2025). Materials used for fabrication variety from non-degradable polymers and metals to biodegradable polymers including polylactic acid (PLA), polyglycolic acid (PGA), and their copolymers, which progressively wreck down after finishing their function, doing away with the want for surgical removal (Fulzele et al., 2022).

In current years, studies in implantable transport has elevated closer to clever and responsive implants, able to freeing tablets in reaction to unique physiological or outside stimuli including pH, temperature, magnetic field, or electric powered signals. These "intelligent" structures constitute a sizeable step towards customized and precision medicine (Huanbutta et al., 2024).

Therefore, implantable drug transport structures have emerged as a critical location of biomedical studies that integrates pharmaceutical science, biomaterials engineering, and medical medicine. This evaluate pursuits to summarize contemporary trends in IDDS, that specialize in their materials, design, mechanisms of drug launch, healing applications, and the demanding situations hindering their sizeable medical adoption.

ADVANTAGES OF IMPLANTABLE DRUG DELIVERY SYSTEM

1.Sustained and Controlled Drug Release

IDDS offer long-time period, managed launch of healing sellers over weeks, months, or maybe years.

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

This minimizes fluctuations in plasma drug stages and keeps consistent healing concentrations, enhancing efficacy and safety .

2.Improved Patient Compliance
Since implants lessen or remove the want for common dosing (e.g., each day tablets or injections), affected person adherence is considerably improved — specifically for persistent situations including most cancers, diabetes, or hormonal remedy.

3.Targeted and Localized Delivery
Drugs may be launched without delay at or close to the goal site, minimizing systemic publicity.
This reduces aspect outcomes and complements neighborhood healing outcomes, that is specially useful in most cancers remedy or localized infections.

4.Reduced Systemic Toxicity
By turning in pills regionally and at managed rates, implantable structures limit systemic toxicity and decrease unfavourable outcomes related to excessive plasma drug peaks.

5.Protection of Labile Drugs
The implant matrix can shield volatile or touchy pills (e.g., peptides, proteins) from enzymatic degradation and vicious organic environments, enhancing bioavailability.

6.Programmability and customization
Many contemporary-day implants permit programmable or responsive launch, the usage of biodegradable polymers, digital controls, or stimuli-responsive materials (e.g., pH, temperature, ultrasound).

7.Reduced Healthcare Burden
Fewer sanatorium visits and much less common dosing lessen usual healthcare expenses and enhance affected person great of life, specially for long-time period therapies.

8.Biocompatibility and Biodegradability
Advances in biomaterials have made implants biocompatible or even biodegradable, putting off the want for surgical elimination and minimizing immune responses.

9.Enhanced Efficacy in Difficult-to-Treat Conditions
Implantable structures are specially fantastic for oncology, persistent ache management, hormonal disorders, and relevant apprehensive gadget diseases, wherein steady and localized drug publicity is critical.

DISADVANTAGE OF IMPLANTABLE DRUG DELIVERY SYSTEM

1.Invasiveness and Surgical Requirements
Implantable structures require minor or foremost surgical tactics for implantation and removal. This will increase the chance of infection, tissue damage, pain, and postoperative complications, making them much less appropriate for sufferers who can't tolerate surgery.

2.Limited Retrievability and Adjustability
Once implanted, it's far frequently tough to retrieve or modify the tool if dosing desires alternate or unfavourable results occur. Unlike oral or injectable routes, dose modulation is restricted after implantation.

3.Biocompatibility and Foreign Body Reaction
The substances utilized in implants can purpose overseas frame reactions, fibrosis, or continual infection on the implantation site. Over time, encapsulation with the aid of using fibrotic tissue might also additionally avoid drug launch kinetics and tool functionality.

4.Device Failure and Drug Stability
Mechanical failure (e.g., leakage, blockage, or degradation of polymer matrix) and drug instability because of temperature, pH, or moisture within the frame can compromise machine reliability and healing effectiveness.

5.Cost and Manufacturing Complexity
Implantable gadgets contain complicated design, manufacturing, and sterilization processes. Their improvement and surgical implantation growth typical healthcare costs, restricting accessibility in low-aid settings.

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

6.Patient Acceptance and Psychological Barriers
Some sufferers can be reluctant to simply accept implanted gadgets because of worry of surgery, frame photograph concerns, or the mental soreness of getting a overseas item interior their frame.

7.Limited Drug Types and Dosing Flexibility
IDDS are higher desirable for potent, strong tablets that require long-term, low-dose release. Drugs with excessive dose necessities or terrible balance might not be appropriate for implant-primarily based totally systems.

CLASSIFICATION OF IMPLANTABLE DRUG DELIVERY SYSTEM

1. Based on Drug Release Mechanism

a. Passive (Rate-Controlled) Systems
These systems rely on diffusion or degradation to control drug release without external energy input.

- Reservoir systems: The drug is enclosed within a polymer membrane that regulates diffusion (e.g., Norplant®).
- Matrix systems: The drug is uniformly dispersed in a biodegradable or non-biodegradable polymer matrix and released as the polymer erodes or through diffusion.

b. Active (Controlled/Triggered) Systems
These use external or internal stimuli to modulate drug release.

- Externally controlled: Release can be triggered by magnetic field, ultrasound, electric current, or heat.
- Internally controlled: Respond to physiological cues such as pH, enzyme activity, or glucose levels.

2. Based on Biodegradability

a. Biodegradable Implants
Made from polymers like polylactic acid (PLA), polyglycolic acid (PGA), or PLGA, which degrade into biocompatible byproducts. They do not require surgical removal, making them ideal for temporary therapies.

b. Non-Biodegradable Implants
Composed of materials such as silicone, ethylene-vinyl acetate (EVA), or polyurethane. These provide long-term delivery but require surgical retrieval after drug depletion.

3. Based on Geometry and Design

- Rod-shaped implants: Common for hormonal delivery (e.g., contraceptive implants).
- Pellets: Small cylindrical implants used in cancer therapy or hormone replacement.
- Disks or sheets: Used for ocular or subcutaneous drug release.
- Micro- and nano-implants: Miniaturized systems for precise and localized delivery.

4. Based on Therapeutic Application

- Hormonal implants: e.g., contraceptive devices delivering levonorgestrel.
- Oncological implants: For localized chemotherapy (e.g., Gliadel® wafer for brain tumors).
- Ophthalmic implants: e.g., Retisert® for chronic uveitis.
- Cardiac and pain management implants: Deliver antiarrhythmic or analgesic drugs.
- Antibiotic-releasing implants: Used in orthopedic and dental infections.

5. Based on Power Source or Control

- Passive systems: Depend solely on diffusion or polymer erosion.
- Electrically or magnetically powered systems: Controlled drug release using microchips or electromagnetic fields.
- Osmotically driven systems: Utilize osmotic pressure to push the drug out at a constant rate (e.g., DUROS® implant).

APLLICATIONS OF IMPLANTABLE DRUG DELIVERY SYSTEM

Implantable drug shipping structures (IDDS) have turn out to be a critical innovation in current therapeutics, offering sustained, localized, and managed drug launch for numerous persistent and localized illnesses. Their capacity to keep regular plasma drug concentrations over prolonged durations extensively improves affected person compliance and healing outcomes. The following are key regions of application:

1. Hormonal Therapy
Implantable structures are notably utilized in hormone substitute and contraceptive therapy.

Contraception: Implants along with Norplant®, Implanon®, and Nexplanon® launch levonorgestrel or etonogestrel regularly for as much as 3–five years, offering long-time period start control.

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

Hormone substitute therapy: Subdermal implants turning in testosterone or estradiol are utilized in treating hormonal deficiencies.

2. Oncology (Cancer Therapy)
IDDS play a crucial position in localized chemotherapy, minimizing systemic toxicity and enhancing drug awareness on the tumor site.

Gliadel® wafer, an FDA-accredited implant, releases carmustine (BCNU) without delay into the mind hollow space post-tumor resection in glioblastoma patients.

Polymer-primarily based totally implants also are being evolved for breast, prostate, and colon cancers to supply anticancer tablets along with paclitaxel or cisplatin domestically.

3. Cardiovascular Diseases
Implantable pumps and polymeric structures are used to supply vasodilators, anticoagulants, or antiarrhythmic tablets without delay into the bloodstream.

For instance, nitroglycerin or verapamil implants may be used for long-time period control of angina or hypertension.

Future traits encompass bioresorbable stents with drug-eluting coatings that save you restenosis after angioplasty.

4. Chronic Pain Management
Implantable infusion pumps offer specific and non-stop shipping of analgesics along with morphine, fentanyl, or baclofen without delay into the intrathecal or epidural space, presenting advanced ache remedy in situations like most cancers ache, neuropathic ache, or spasticity.

five. Diabetes Management

Osmotic or sensor-managed implants are being evolved for insulin shipping.

These structures can keep basal insulin tiers and modify launch costs in reaction to blood glucose concentrations, decreasing the weight of more than one every day injections.

6. Ophthalmic Disorders
Ocular implants supply tablets without delay to the eye, bypassing limitations like tear drainage or confined corneal permeability.

Retisert® and Iluvien® implants launch fluocinolone acetonide to deal with persistent non-infectious uveitis and diabetic macular edema.

These gadgets offer sustained intraocular drug launch for months to years, minimizing the want for repeated injections.

7. Neurological Disorders
Neural implants are hired withinside the remedy of Parkinson`s disease, epilepsy, and schizophrenia.

Controlled shipping of medication along with levodopa, dopamine agonists, or antipsychotics through implants facilitates keep strong plasma tiers and decrease fluctuations in symptoms.

Future instructions encompass microchip-primarily based totally neural drug implants able to on-call for drug launch.

8. Orthopedic and Dental Applications
Antibiotic- or boom factor-loaded implants are used to save you infections and beautify bone regeneration.

In orthopedics, implants liberating gentamicin or vancomycin lessen postoperative contamination risks.

In dentistry, bioerodible implants can domestically supply chlorhexidine or tetracycline for periodontal therapy.

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

9. Immunotherapy and Vaccination

Long-performing vaccine implants able to managed antigen launch are being evolved to result in extended immune responses. These are mainly promising for persistent infectious illnesses along with HIV, tuberculosis, and hepatitis.

CONCLUSION

Implantable drug transport structures (IDDS) have emerged as a promising development in pharmaceutical technology, supplying sustained, targeted, and managed drug launch that complements healing efficacy and affected person compliance. These structures offer vast advantages withinside the control of continual sicknesses which includes cancer, hormonal disorders, ocular sicknesses, and continual pain, in which long-time period and localized remedy is essential.

However, in spite of their advantages, IDDS face demanding situations which includes invasive surgical implantation, restrained retrievability, biocompatibility concerns, production complexity, and excessive cost. These obstacles have slowed their good sized scientific adoption. Current studies is consequently targeted on growing biodegradable, stimuli-responsive, and clever implantable structures able to handing over pills exactly and safely, with minimum affected person discomfort.

In the future, integrating nanotechnology, biosensors, and micro-electromechanical structures (MEMS) into implantable gadgets ought to permit personalized, on-demand, and remotely controllable drug transport. With endured interdisciplinary innovation, implantable drug transport structures keep the capacity to convert healing exercise and form the subsequent era of precision medicine.

REFERENCE

1. *Amreen S, Shahidulla SM, Sultana A, Fatima N. "Implantable Drug Delivery System: An Innovative Approach." Journal of Drug Delivery & Therapeutics. 2023;13(5):98-105. DOI:10.22270/jddt.v13i5.6069.*
2. *Malik, J. (2013). A review on implantable drug delivery system. PharmaTutor. October 11, 2013. Retrieved from https://www.pharmatutor.org/articles/review-implantable-drug-delivery-system PharmaTutor*
3. *Fulzele, S., Bavaskar, S. R., Gayakwad, B. P., Sawale, J., Yadav, R., & Gauttam, V. (2022). An overview on implantable drug delivery system. Journal of Pharmaceutical Research International, 34(25A), 1–13. https://doi.org/10.9734/jpri/2022/v34i25A35942 J Pharm Res Int*
4. *Amreen, S., Shahidulla, S. M., Sultana, A., & Fatima, N. (2023). Implantable drug delivery system: An innovative approach. Journal of Drug Delivery & Therapeutics, 13(5), 98-105. Drug Delivery Journal*
5. *Huanbutta, K., Puri, V., Sharma, A., Singh, I., Sriamornsak, P., & Sangnim, T. (2024). Rise of implantable drugs: A chronicle of breakthroughs in drug delivery systems. Saudi Pharmaceutical Journal, 32(12), 102193. https://doi.org/10.1016/j.jsps.2024.102193 RCA Storage+1*
6. *Del Bono, F., Di Trani, N., Demarchi, D., Grattoni, A., & Motto Ros, P. (2025). Active implantable drug delivery systems: Engineering factors, challenges, opportunities. Lab on a Chip, 25, 3608-3629. https://doi.org/10.1039/D5LC00131E*
7. *Park, K. (2014). Implantable drug delivery systems: An overview. Journal of Controlled Release, 190, 3–8. https://doi.org/10.1016/j.jconrel.2014.03.057 → A comprehensive overview of implantable systems, materials, and clinical applications.*
8. *Langer, R., & Peppas, N. A. (2003). Advances in biomaterials, drug delivery, and bio nano technology. AIChE Journal, 49(12), 2990–3006. https://doi.org/10.1002/aic.690491202 → Discusses controlled release technologies and implantable systems in biomedical engineering.*
9. *Patil, Y. B., Toti, U. S., & Burgess, D. J. (2019). Implantable drug delivery systems: Challenges and recent advances. Drug Delivery and Translational Research, 9, 1053–1071. https://doi.org/10.1007/s13346-019-00660-6 → Focuses on the technological evolution and clinical translation of implantable drug delivery.*
10. *Zhao, Y., et al. (2020). Recent advances in implantable drug delivery systems. Biomaterials Science, 8(10), 2719–2735. https://doi.org/10.1039/D0BM00173H → Reviews modern implant materials and responsive release mechanisms.*
11. *Garg, T., & Singh, O. (2012). Review on implantable drug delivery system: An overview. International Journal of Pharmacy and Pharmaceutical Sciences, 4(2), 1–8. → Summarizes design types, advantages, and biocompatibility issues.*
12. *Feng, S. S. (2004). Nanoparticles of biodegradable polymers as drug delivery systems for clinical administration: an overview. Journal of Controlled Release, 100(1), 1–4.*

SJIF Impact Factor (2025): 8.688| ISI I.F. Value: 1.241| Journal DOI: 10.36713/epra2016 ISSN: 2455-7838(Online)
EPRA International Journal of Research and Development (IJRD)
Volume: 10 | Issue: 10 | October 2025 - Peer Reviewed Journal

https://doi.org/10.1016/j.jconrel.2004.08.005
→ Discusses polymer-based systems often used in implantable formulations.
13. *Zaki AJ, Patil SK, Baviskar DT, Jain DK. Implantable Drug Delivery System: A Review. Int. J. PharmTech Res. 2012;4(1):280-292. Courseware*
14. *Stewart SA, et al. Implantable Polymeric Drug Delivery Devices. PubMed Central. 2018. PMC*
15. *Rajesh Bharad V, Sheikh A A, Kale R H, Biyani K R. Implantable Drug Delivery Systems: An Updated Review. Int. J. Pharm. Chem. & Biol. Sci. 2021;11(3):01-07. ijpcbs.com*
16. *Amreen S, Shahidulla S M, Sultana A, Fatima N. Implantable Drug Delivery System: An Innovative Approach. J Drug Deliv Ther. 2023;13(5):98-105. Drug Delivery Journal*
17. *Fulzele S, Bavaskar S R, Gayakwad B P, Sawale J, Yadav R, Gauttam V. "An Overview on Implantable Drug Delivery System." J Pharm Res Int. 2022;34(25A):1-13*
18. *Zaki AJ, Patil SK, Baviskar DT, Jain DK. Implantable Drug Delivery System: A Review. Int. J. PharmTech Res. 2012;4(1):280-292.*
19. *Stewart SA, et al. Implantable Polymeric Drug Delivery Devices. Adv Drug Deliv Rev. 2018;127:19-46.*
20. *Bharad VB, Sheikh AA, Kale RH, Biyani KR. Implantable Drug Delivery Systems: An Updated Review. Int. J. Pharm. Chem. Biol. Sci. 2021;11(3):01-07.*
21. *Amreen S, et al. Implantable Drug Delivery System: An Innovative Approach. J Drug Deliv Ther. 2023;13(5):98-105.*
22. *Stewart SA, et al. Implantable Polymeric Drug Delivery Devices. Adv Drug Deliv Rev. 2018;127:19–46.*
23. *Zaki AJ, Patil SK, Baviskar DT, Jain DK. Implantable Drug Delivery System: A Review. Int. J. PharmTech Res. 2012;4(1):280–292.*
24. *Bharad VB, Sheikh AA, Kale RH, Biyani KR. Implantable Drug Delivery Systems: An Updated Review. Int. J. Pharm. Chem. Biol. Sci. 2021;11(3):01–07.*
25. *Amreen S, et al. Implantable Drug Delivery System: An Innovative Approach. J Drug Deliv Ther. 2023;13(5):98–105.*
26. *Santini JT, Cima MJ, Langer R. A Controlled-Release Microchip. Nature. 1999;397(6717):335–338.*